Jingfeng Pharmaceutical(SZ:000908) Mei Ri Jing Ji Xin Wen·2025-08-24 08:14Group 1 - The core viewpoint of the article highlights ST Jingfeng's financial performance, indicating a decline in revenue and continued net losses in the first half of 2025 compared to the previous year [1] - ST Jingfeng reported an operating revenue of approximately 183 million yuan for the first half of 2025, representing a year-on-year decrease of 9.47% [1] - The net loss attributable to shareholders for the same period was approximately 32.57 million yuan, with a basic loss per share of 0.037 yuan [1] - In comparison, the operating revenue for the first half of 2024 was about 203 million yuan, with a net loss of approximately 33.05 million yuan and a basic loss per share of 0.0376 yuan [1] Group 2 - As of the report, ST Jingfeng's market capitalization stands at 5.2 billion yuan [2]